Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901).The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI), 0.53-0.86; p=0.0013].1 Median progression-free survival (PFS) was not reached after nearly five years and the PFS benefit observed with D-Rd was maintained, with a 47 percent reduction in risk of disease progression or death [HR: 0.53; 95 percent CI, 0.43-0.66; p
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Allergy & Immunology | Anaphylactic Shock | Anemia | Biotechnology | Blood Transusion | Brain | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemotherapy | Child Development | Children | Chronic Leukemia | Chronic Obstructive Pulmonary | Chronic Pain | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Databases & Libraries | Dexamethasone | Emergency Medicine | Food and Drug Administration (FDA) | France Health | Hay Fever | Health Management | Heart | Heart Transplant | Hematology | Hospitals | Hypertension | Infectious Diseases | Internet | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Laryngeal Cancer | Learning | Legislation | Leukemia | Myeloma | Neurology | Neuroscience | Oral Cancer | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Politics | Prednisone | Pregnancy | Pulmonary Hypertension | Respiratory Medicine | Revlimid | Science | Statistics | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Toxicology | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology | Vaccines | Velcade | Warnings | Women